Johnson & Johnson orthopedic sales up 1.2% in Q3: 5 things to know

Laura Dyrda -   Print  |

Johnson & Jonson reported its orthopedics line had a 1.2 percent increase in sales for the third quarter.

Five things to know:

1. Worldwide orthopedics sales hit $2.1 billion, a 1.2 percent increase compared to the same period last year. Both U.S. and international sales were up 1.2 percent, to $1.3 billion and $837 million, respectively.

2. U.S. knee sales were down 2.7 percent to $209 million, but international sales jumped nearly 8 percent to $136 million. Overall knee sales for the quarter were $344 million, a 1.2 percent increase.

3. Spine and other sales were down nearly 1 percent worldwide to $778 million. In the U.S., spine and other sales were relatively flat at $472 million, but international sales were down 2 percent to $306 million.

4. Hip sales in the U.S. were up 1.1 percent to $204 million while international sales were up 2.7 percent to $133 million. Overall hip sales increased 1.7 percent to $336 million.

5. Trauma sales in the U.S. were up 5.1 percent to $415 million while international sales were up 1 percent to $262 million. Overall trauma sales increased 3.5 percent to $677 million.

More articles on orthopedic devices:
15 hospitals installing robots for spine, orthopedics in 2019
Excelsior Orthopaedics merger complete, brings group to 90 providers
145 orthopedic surgeon moves in 2019 through Q3

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers